Cette journée a eu lieu le vendredi 16 octobre 09, au Musée des Moulages de l’Hôpital Saint-Louis à Paris, 1 avenue Claude vellefaux, 75010.
Le programme est le suivant :
8h30 : Accueil des congressistes
9h00-9h10 : INTRODUCTION - Louis Dubertret
9h10-9h30 : PSORIASIS, GROSSESSE ET CONTRACEPTION - Selim Aractingi
9h40-10h00 : PARTICULARITES DU PSORIASIS DE L’ENFANT - Christine Bodemer
10h00-10h30 : QUAND LE PSORIASIS MET LA VIE EN DANGER - Hervé Bachelez
10h40-11h00 : Pause
11h00-11h20 : PSORIASIS ET EDUCATION THERAPEUTIQUE - Carle Paul
11h30-12h10 : CAS CLINIQUES INTERACTIFS - Catherine Goujon, Michel Le Maître
12h10-13h30 : Déjeuner
13h30-13h50 : EVALUATION DES RISQUES CARDIOVASCULAIRES CHEZ UN PSORIASIQUE - Alain Simon
14h00-14h20 : UTILISATION AU LONG COURS DES TRAITEMENTS ANTI-PSORIASIQUES - Louis Dubertret
14h30-14h50 : LES NOUVELLES CIBLES THERAPEUTIQUES DANS LE PSORIASIS - Martine Bagot
15h00-15h20 : LES BIOTHERAPIES EN PRATIQUE - Catherine Goujon
15h30-15h50 : Pause
15h50-17h00 : CAS CLINIQUES INTERACTIFS (SUITE) - Marie Beylot-Barry, François Aubin, Vincent Descamps
Contact : Christina Pitton - Groupe Français du Psoriasis
Hôpital Saint-Louis, Pavillon Bazin
1 avenue Claude Vellefaux, 75010 Paris
Tel : 01 53 72 20 60 - Fax : 01 53 72 20 61
email : clubfrancaisdupsoriasis@gmail.com
www.psoriasis-international.org/gfp
Les résumés de la journée sont accessibles en cliquant ici
L’accès aux diaporamas des différentes conférences est restreint, inscrivez-vous pour y avoir accès.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.
Arch Dermatol Res.
2021 Apr , 313, (3):163-171.
Psoriasis, hidradenitis, and atopic dermatitis (AD) are associated with increased cardiometabolic comorbidities. Yet, little is known about screening rates for cardiometabolic comorbidities in patients with these disorders. The objective of this study is to determine rates and predictors of cardiovascular screening among patients with psoriasis, AD, and hidradenitis in the United States. Data from the 2006-2015 National Ambulatory Medical Care Survey were analyzed, including 67,581 (...)
see on pubmed
Nanoliposomes@Transcutol for Skin Delivery of 8-Methoxypsoralen.
Sinico C et al.
Nanoliposomes@Transcutol for Skin Delivery of 8-Methoxypsoralen.
J Nanosci Nanotechnol.
2021 May 01, 21, (5):2901-2906.
8-methoxypsoralen is the most common drug in psoralen plus ultraviolet light irradiation therapy for the treatment of severe psoriasis. Despite of the efficacy, its classic oral administration leads to several serious adverse effects. However, the topical psoralen application produces a drug skin accumulation lower than that obtained by oral administration, due to the drug low skin permeability. In this paper, 8-methoxypsoralen loaded Penetration Enhancer-containing Vesicles were prepared (...)
see on pubmed
Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.
Bioengineered.
2021 Dec , 12, (1):183-195.
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide population, and causing long-term troubles to the patients. Therefore, it is urgent to develop safe and effective therapeutic drugs. Catalpol is a natural iridoid glucoside, that has several remarkable pharmacological effects, however, whether catalpol can alleviated psoriasis has not been explored. The goal of the present work is to study the role of catalpol in psoriasis in vivo and in vitro. (...)
see on pubmed
on Atopic Dermatitis
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.
Arch Dermatol Res.
2021 Apr , 313, (3):163-171.
Psoriasis, hidradenitis, and atopic dermatitis (AD) are associated with increased cardiometabolic comorbidities. Yet, little is known about screening rates for cardiometabolic comorbidities in patients with these disorders. The objective of this study is to determine rates and predictors of cardiovascular screening among patients with psoriasis, AD, and hidradenitis in the United States. Data from the 2006-2015 National Ambulatory Medical Care Survey were analyzed, including 67,581 (...)
see on pubmed
Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF-κB signaling pathways.
J Ethnopharmacol.
2021 Apr 24, 270:113773.
Qingxue jiedu Formulation (QF) is composed of two classic prescriptions which have been clinically used for more than 5 centuries and appropriately modified through basic theory of traditional Chinese medicine for treating various skin inflammation such as atopic dermatitis (AD), acute dermatitis and rash. Although QF possesses a prominent clinical therapeutic effect, seldom pharmacological studies on its anti-AD activity are (...)
see on pubmed
Methicillin-resistant from infected skin lesions present several virulence genes and are associated with the CC30 in Brazilian children with atopic dermatitis.
Virulence.
2021 Dec , 12, (1):260-269.
Atopic dermatitis (AD) is a chronic inflammatory skin disease and colonization by may affect up to 100% of these patients. Virulent and resistant isolates can worsen AD patient clinical condition and jeopardize the treatment. We aimed to detect virulence genes and to evaluate the biofilm production of isolates from infected skin lesions of children with AD. Methicillin resistance was detected by phenotypic and molecular tests and the virulence genes were detected by PCR. Biofilm formation (...)
see on pubmed
